Clinical Trials Logo

Hemochromatosis clinical trials

View clinical trials related to Hemochromatosis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05238207 Terminated - Clinical trials for Hereditary Hemochromatosis

A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers

Start date: March 28, 2022
Phase: Phase 1
Study type: Interventional

This is a first in human, double-blind, randomized, placebo-controlled, two-arm crossover study evaluating the safety, tolerability and PD of ascending dose levels of BBI-001 after: - a single administration in iron deficient male and female participants, and male and female HH patients (Part A), - two administrations per day in HH patients (Part B). BBI-001 administrations will be accompanied with consumption of a meal enriched with stable iron isotope Fe57, while corresponding placebo dose administrations will be with a meal enriched with stable iron isotope Fe58.

NCT ID: NCT04284371 Terminated - Obesity, Childhood Clinical Trials

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients

Start date: February 10, 2016
Phase:
Study type: Observational

The prevalence of liver steatosis, steatohepatitis, fibrosis, and hemosiderosis in overweight and obese US Military dependent pediatric patients using MR Elastography and Quantitative MRI

NCT ID: NCT02263638 Terminated - Clinical trials for Refractory Hemochromatosis Rheumatism

Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study

THERA
Start date: February 4, 2015
Phase: Phase 2
Study type: Interventional

Treatment of refractory hemochromatosis rheumatism by Anakinra. Prospective, multicenter, non-randomised, single-arm, open-label, phase II trial.

NCT ID: NCT00122980 Terminated - Clinical trials for Cerebrovascular Accident

Stroke With Transfusions Changing to Hydroxyurea

Start date: October 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with sickle cell anemia (SCA).